SCHEMBL954925

SCHEMBL954925

CN1CCN(CCC(=O)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.57
PAOX Q6QHF9 1/20 0.53
CYP1A2 P05177 2/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
APEX1 P27695 1/20 0.46
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1128075 0.98 GLA (0.61) GLAPAOXCYP1A2MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL23453856 0.98 GLA (0.61) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL8194848 0.98 GLA (0.55) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL21122189 0.92 GLA (0.50) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL24732015 0.92 CYP1A2 (0.52) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL3973280 0.90 GLA (0.67) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL1069692 0.90
SCHEMBL6536452 0.90 GLA (0.67) GLAPAOXCYP1A2MAPK1SMN1; SMN2
SCHEMBL7027263 0.90 GLA (0.67) GLAPAOXCYP1A2MAPK1SMN1; SMN2
Propane SCHEMBL1995071 0.88 GLA (0.59) GLAPAOXCYP1A2MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025080945-A1 LIPID NANOPARTICLES CodeBridgeBio Inc. (US) 2025-04-17 WO claimed
EP-2968145-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS Mallinckrodt LLC (US) 2016-01-20 EP claimed
CN-105188675-A Modified docetaxel liposome formulations MALLINCKRODT LLC 2015-12-23 CN claimed
WO-2014160392-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS MALLINCKRODT LLC (US) 2014-10-02 WO claimed
WO-2000026195-A1 NOVEL AMINO ACID HETEROCYCLIC AMIDE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 2000-05-11 WO claimed
EP-0494956-B1 AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS COSAN CHEM CORP (US) 1995-12-13 EP claimed
US-20260115138-A1 LIPID NANOPARTICLES CODEBRIDGEBIO INC (US) 2026-04-30 US disclosed
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
EP-3858849-B1 DERIVATIVE BASED ON COMMON ANEMARRHENAE RHIZOME SARSASAPOGENIN STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PHYTOVENT BIOPHARMA (CN) 2026-02-11 EP disclosed
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 US disclosed
EP-4635939-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING SAME Korea Institute of Science and Technology (KR) 2025-10-22 EP disclosed
US-12448410-B2 Derivative of sarsasapogenin, pharmaceutical composition and use thereof PHYTOVENT BIOPHARMA (CN) 2025-10-21 US disclosed
US-12427111-B2 Lipid nanoparticles CodeBridgeBio Inc. (US) 2025-09-30 US disclosed
WO-2002066462-A1 PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION GLAXO GROUP LIMITED (GB) 2002-08-29 WO disclosed
WO-2002004434-A1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS ANGIOGENE PHARMACEUTICALS LIMITED (GB) 2002-01-17 WO disclosed
WO-2000023419-A1 NOVEL PRODRUGS OF NON-STEROIDAL ANTI-INFLAMMATORY CARBOXYLIC ACIDS, THEIR PREPARATION AND USE JAERVINEN TOMI (FI) 2000-04-27 WO disclosed
EP-0494956-B1 AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS COSAN CHEM CORP (US) 1995-12-13 EP disclosed
EP-0494956-A4 AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS 1993-07-21 EP disclosed
EP-0494956-A1 AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS. COSAN CHEM CORP (US) 1992-07-22 EP disclosed
WO-1991004952-A1 AMINOCARBOXYLATE SALTS AS CORROSION INHIBITORS IN COATING APPLICATIONS COSAN CHEMICAL CORPORATION (US) 1991-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115138-A1 LIPID NANOPARTICLES LDLR, CETP, PLIN3 GLA 3886/4885PAOX 587/4885CYP1A2 4669/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 GLA 2296/4885PAOX 2033/4885CYP1A2 3069/4885
US-12427111-B2 Lipid nanoparticles PNLIP, PLIN3, LIPG GLA 2929/4885PAOX 802/4885CYP1A2 4683/4885
US-12448410-B2 Derivative of sarsasapogenin, pharmaceutical composition and use thereof SARS1, ACE2, FURIN GLA 464/4885PAOX 3066/4885CYP1A2 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.